Edition:
United States

Cellectis SA (ALCLS.PA)

ALCLS.PA on Paris Stock Exchange

22.75EUR
21 Jul 2017
Change (% chg)

€0.07 (+0.31%)
Prev Close
€22.68
Open
€22.70
Day's High
€22.92
Day's Low
€22.40
Volume
61,048
Avg. Vol
65,716
52-wk High
€25.75
52-wk Low
€14.08

Latest Key Developments (Source: Significant Developments)

Cellectis announces subsidiary's Calyxt’s IPO
Thursday, 20 Jul 2017 01:42am EDT 

July 20 (Reuters) - CELLECTIS SA ::ANNOUNCES SUBSIDIARY'S CALYXT’S INITIAL PUBLIC OFFERING OF 7,000,000 SHARES.THE INITIAL PUBLIC OFFERING PRICE OF $8.00 PER SHARE, DECREASE FROM THE PREVIOUSLY DISCLOSED ESTIMATED PRICE RANGE OF $15.00 TO $18.00 PER SHARE.OFFERING IS EXPECTED TO CLOSE ON OR ABOUT JULY 25, 2017.  Full Article

Cellectis says Calyxt prices $56 mln initial public offering
Wednesday, 19 Jul 2017 06:33pm EDT 

July 19 (Reuters) - Cellectis SA - :Cellectis: Calyxt announces pricing of $56.0 million initial public offering.Pricing of Calyxt's initial public offering of 7 million shares of common stock at IPO price of $8.00 per share.  Full Article

Cellectis announces proposed Calyxt IPO of $100.0 million
Monday, 10 Jul 2017 07:06am EDT 

July 10 (Reuters) - CELLECTIS SA :CELLECTIS: CALYXT ANNOUNCES PROPOSED INITIAL PUBLIC OFFERING OF $100.0 MILLION.‍CALYXT IS CELLECTIS' 100% OWNED GENE EDITING AGRICULTURE COMPANY​.‍CITIGROUP, JEFFERIES AND WELLS FARGO SECURITIES ARE ACTING AS JOINT BOOK-RUNNING MANAGERS​.‍BMO CAPITAL MARKETS AND LADENBURG THALMANN ARE ACTING AS CO-MANAGERS​.‍ESTIMATED PRICE RANGE FOR INITIAL PUBLIC OFFERING IS $15.00 TO $18.00 PER SHARE OF COMMON STOCK​.  Full Article

Calyxt Inc sees IPO of 6,060,606 shares of its common stock
Monday, 10 Jul 2017 07:06am EDT 

July 10 (Reuters) - Cellectis SA ::Calyxt Inc sees ipo of 6,060,606 shares of its common stock .Calyxt Inc says anticipates that its ipo will be priced between $15.00 and $18.00 per share of common stock.Calyxt Inc says it has applied to list its common stock on nasdaq under the symbol "CLXT".Calyxt Inc adds BMO capital markets to its list of underwriters.  Full Article

Cellectis to explore possible IPO of Calyxt
Wednesday, 12 Apr 2017 05:00pm EDT 

Cellectis Sa : Cellectis s.a. To explore possible initial public offering of Calyxt, Inc. . No decisions have been taken at this point on structure or timing of any IPO . Is exploring possibility of an initial public offering (ipo) of a minority interest in its plant sciences business, Calyxt, inc .No assurance can be given that an IPO will be pursued.  Full Article

Servier, Pfizer announce FDA clearance of IND application for UCART19
Thursday, 9 Mar 2017 02:04am EST 

Pfizer Inc : Servier and Pfizer announce FDA clearance of IND application for UCART19 in adult relapsed/refractory acute lymphoblastic leukemia .Pfizer inc - U.S. FDA has granted Servier with an investigational new drug clearance to proceed in U.S. With clinical development of UCART19.  Full Article

Cellectis SA reports fourth quarter results
Monday, 6 Mar 2017 04:30pm EST 

Cellectis SA : Cellectis reports 4th quarter and full year 2016 financial results . Cellectis SA - revenues and other income of $56 million in 2016 . Cellectis SA - during quarters ended december 31, 2015 and 2016, recorded eur29.2 million and eur12.1 million, respectively, in revenues and other income . Cellectis SA - during quarters ended december 31, 2015 and 2016, recorded a net gain of eur8.2 million and net loss of eur12.5 million .Cellectis SA - adjusted income attributable to shareholders of cellectis for q4 was eur0.6 million versus eur20.9 million.  Full Article

FDA grants Cellectis IND approval to proceed with development of UCART123
Monday, 6 Feb 2017 04:30pm EST 

Cellectis SA : FDA grants cellectis IND approval to proceed with the clinical development of UCART123, the first gene edited off-the-shelf car t-cell product candidate developed in the U.S. .Intends to initiate phase 1 trials in first half of 2017.  Full Article

Cellectis submits IND application for UCART123
Tuesday, 3 Jan 2017 05:00pm EST 

Cellectis Sa : Cellectis submits IND application for UCART123, an allogeneic gene edited car t-cell product candidate, in AML and BPDCN .Cellectis sa says pending regulatory clearance, plans to initiate phase 1 clinical trials in first half of 2017.  Full Article

Cellectis Announces the Issuance of US Patent 9,458,439
Wednesday, 5 Oct 2016 02:03am EDT 

Cellectis SA : Announced on Tuesday the issuance of U.S. patent 9,458,439 – which claims gene inactivation by use of chimeric restriction endonucleases .This patent granted by the USPTO to the Institut Pasteur and Boston Children's Hospital naming Dr Andre Choulika and Pr. Richard C. Mulligan as co-inventors, is exclusively licensed to Cellectis.  Full Article

BRIEF-Cellectis announces subsidiary's Calyxt’s IPO

* ANNOUNCES SUBSIDIARY'S CALYXT’S INITIAL PUBLIC OFFERING OF 7,000,000 SHARES